Your browser doesn't support javascript.
loading
Potential Significant Changes in Nuclear Regulatory Commission Policies Regarding Training and Experience Requirements for the Use of Radiopharmaceuticals.
Wallner, Paul E; Lieto, Ralph P; Dillehay, Gary L; Ghesani, Munhir V; Rosenthal, Seth A; Rosenzweig, Kenneth E; Steinberg, Michael L; Yoo, Don C; Small, William.
Afiliación
  • Wallner PE; 21st Century Oncology, Moorestown, New Jersey; Chair, Work Group of the ACR Commission on Government Relations, Federal Regulatory Committee; Chair, Physicians Consortium for Performance Improvement, Oncology Technical Expert Panel. Electronic address: paul.wallner@21co.com.
  • Lieto RP; Monroe, Michigan.
  • Dillehay GL; Feinberg School of Medicine, Chicago, Illinois.
  • Ghesani MV; Chief of Nuclear Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Rosenthal SA; Sutter Medical Group, Sacramento, California.
  • Rosenzweig KE; Icahn School of Medicine at Mount Sinai, New York, New York; Chair, Department of Radiation Oncology, Mount Sinai Health System, New York, New York; Vice Chair, ACGME Radiation Oncology Review Committee.
  • Steinberg ML; David Geffen School of Medicine at UCLA, Los Angeles, California; Chair, Radiation Oncology, University of California, San Francisco, San Francisco, California.
  • Yoo DC; The Warren Alpert Medical School of Brown University, Providence, Rhode Island; Chair, ACR Commission on Nuclear Medicine and Molecular Imaging.
  • Small W; Chair, Department of Radiation Oncology, and Director, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, Illinois; Co-Chair, NRG Oncology Gynecologic Cancer Committee; Chair, ACR Commission on Radiation Oncology.
J Am Coll Radiol ; 18(2): 312-317, 2021 Feb.
Article en En | MEDLINE | ID: mdl-32860755
The Code of Federal Regulations is a single-source repository of all rules and regulations promulgated by federal departments and agencies. In Title 10, Chapter 1, Part 35, Subpart D, §§35.100 to 35.290 detail regulations for the use of unsealed by product material not requiring a written directive (ie, diagnostic radiopharmaceuticals), and in Subpart E, §§35.300 to 35.396 detail regulations for the use of unsealed by product material requiring a written directive (ie, therapeutic radionuclides). Currently proposed changes for both Subparts D and E could have profound effects on patient care, public safety, and the practice of nuclear medicine, diagnostic radiology, and radiation oncology. This article details those proposed changes and actions under way to prevent promulgation of proposals that could negatively affect patient care and public safety.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radiofármacos / Medicina Nuclear Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: J Am Coll Radiol Asunto de la revista: RADIOLOGIA Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radiofármacos / Medicina Nuclear Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: J Am Coll Radiol Asunto de la revista: RADIOLOGIA Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos